AUTHOR=Cui Zhenzhen , Liu Le , Chen Xi , Zeng Haiyan , Zheng Shizhu , Wu De 

TITLE=Single Blind Randomized Controlled Trial of Modified Constraint-Induced Movement Therapy in Infants With the Sequelas of Unilateral Brachial Plexus Injury

JOURNAL=Frontiers in Human Neuroscience

VOLUME=16

YEAR=2022

URL=https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2022.900214

DOI=10.3389/fnhum.2022.900214

ISSN=1662-5161

ABSTRACT=<sec><title>Objective</title><p>To explore the effect of modified constraint-induced movement therapy (mCIMT) on upper limbs residual dysfunction for infancy with the sequelas of unilateral brachial plexus injury (uBPI).</p></sec><sec><title>Methods</title><p>Single blind randomized controlled trial of mCIMT vs. standard care. An enrolling 31 infants with a uBPI exhibiting residual dysfunction of the affected upper limb for over 6 months was conducted. And functional outcomes pertaining to the affected upper limb were assessed <italic>via</italic> AMS, GRES, RHS, and MSS at 0, 3, and 6 months after treatment.</p></sec><sec><title>Results</title><p>No differences were found in baseline (acquisition phase) AMS, MSS, GRES, or RHS between the control and mCIMT groups [<italic>F</italic>(1, 14) = 0.062, <italic>P</italic> = 0.086; <italic>F</italic>(1, 14) = 0.483, <italic>P</italic> = 0.499; <italic>F</italic>(1, 14) = 0.272, <italic>P</italic> = 0.610; <italic>Z</italic> = −0.336, <italic>P</italic> = 7.373]. At the 3- and 6-month follow-up time points, AMS, MSS, and GRES scores were significantly improved over baseline in both groups [mCIMT: <italic>F</italic>(2, 30) = 183.750, 128.614, 110.085, <italic>P</italic> &lt; 0.05; Control: <italic>F</italic>(2, 28) = 204.007, 75.246, 51.070, <italic>P</italic> &lt; 0.05]. No significant differences were found between two treatment groups at the 3-month follow-up time point [<italic>F</italic>(1, 14) = 0.565, <italic>P</italic> = 0.465; <italic>F</italic>(1, 14) = 0.228, <italic>P</italic> = 0.641; <italic>F</italic>(1, 14) = 0.713, <italic>P</italic> = 0.413; <italic>Z</italic> = −0.666, <italic>P</italic> = 0.505]. However, at the 6-month follow-up time point, AMS and MSS scores were significantly improved in the mCIMT group relative to the control group [<italic>F</italic>(1, 14) = 8.077, <italic>P</italic> = 0.013; <italic>F</italic>(1, 14) = 18.692, <italic>P</italic> = 0.001].</p></sec><sec><title>Conclusion</title><p>mCIMT may benefit the rehabilitation of residual upper limb dysfunction associated with a uBPI in infants.</p></sec><sec><title>Clinical Trial Registration</title><p>[<ext-link ext-link-type="uri" xlink:href="https://www.chictr.org.cn" xmlns:xlink="http://www.w3.org/1999/xlink">www.chictr.org.cn</ext-link>], identifier [ChiCTR1900022119].</p></sec>